Summer information hub offers in-person help with Nunavut Health Card at Qikiqtani General Hospital - Government of Nunavut

A file photo of an active tuberculosis case. (Rajesh Kumar Singh/Associated Press) ‘TB elimination by 2030 it is an ambitious goal, but it is also within our reach’

NorthNunavut officials say the territory’s goal of eliminating tuberculosis by 2030 is still within reach, despite more cases this year than last.‘TB elimination by 2030 it is an ambitious goal, but it is also within our reach’CBC News · Posted: Oct 13, 2026 2:14 PM EDT | Last Updated: October 13Listen to this articleEstimated 8 minutesThe audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Examining Nunavut's continuing fight against tuberculosisOctober 9|Duration 2:29Tuberculosis has played a huge role in the history of Nunavut. The disease has caused deaths, relocations and a lot of suffering. Though progress has been made to eradicate it, it's far from gone in the territory. Arty Sarkisian reports. Nunavut officials say the territory’s goal of eliminating tuberculosis by 2030 is still within reach, despite more cases this year than last. In an update in early October, the territory’s Department of Health reported 32 active cases of TB in the first three quarters of 2026 across seven communities.

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.